What is the role of caplacizumab (Cablivi) in the treatment of thrombotic thrombocytopenic purpura (TTP)?

Updated: May 25, 2021
  • Author: Theodore Wun, MD, FACP; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

Caplacizumab (Cablivi), a nanobody that targets von Willebrand factor (vWF) was approved by the FDA in January 2019. It is indicated for acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It has been shown to reduce time to platelet count response and also to reduce aTTP-related death, recurrence, or major thromboembolic events. [5]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!